MedTrace Logo

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

NCT00243347 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2013-10-17

Study results available
· View outcomes & findings →

Summary

This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.

Conditions

  • Carcinoma
  • Non-Small-Cell Lung Carcinoma
  • Head and Neck Neoplasms

Interventions

DRUG

AZD2171

oral tablet

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Oncology Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-05-31
Completion
2009-07-31

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243347 on ClinicalTrials.gov